AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04695990
Drug: Wenyang Huoxue Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenyang Huoxue granules
Trial: NCT04695990
Drug: Wenyang Huoxue placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
Trial: NCT06010680
Drug: [14C]SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
Trial: NCT06632080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Trial: NCT06058091
Drug: RY_SW01 cell injection
RxNorm normalized name: phenylephrine tannate / pyrilamine tannate Oral Suspension [Ry-T-12]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer basic treatment with an injection of RY_SW01 cell solution
Trial: NCT06058091
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment for SSc
Trial: NCT06357104
Drug: Pravastatin Sodium 20 MG
RxNorm normalized name: pravastatin sodium 20 MG
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
Trial: NCT06341335
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv, q3w
Trial: NCT05006664
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment by study drug Doxorubicin in combination.
Trial: NCT06564584
Drug: TLC-2716 Dose 1
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT06564584
Drug: TLC-2716 Dose 2
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT06564584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT05766605
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Trial: NCT05766605
Drug: Oxaliplatin, Leucovorin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions
Trial: NCT04881760
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04881760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04769869
Drug: AZD4604 for inhalation via DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Trial: NCT04769869
Drug: Placebo for AZD4604 for inhalation via DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10.
Trial: NCT04769869
Drug: AZD4604 for inhalation via DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
Trial: NCT04943679
Drug: Anti-PD-1/PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection for up to 2 years
Trial: NCT04368819
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Trial: NCT06080555
Drug: Ferric Carboxymaltose Injection [Ferinject]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
Trial: NCT05772871
Drug: Huaiqihuang granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Trial: NCT05772871
Drug: Huaiqihuang Granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Trial: NCT05270863
Drug: BRIMOCHOL™ PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single drop in each eye at a visit.
Trial: NCT06194656
Drug: HER3 Monoclonal antibodies-Dose C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Trial: NCT04681144
Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
Trial: NCT05465304
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
Trial: NCT06426979
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
Trial: NCT04682665
Drug: Icosapent Ethyl Oral Capsule
RxNorm normalized name: icosapent ethyl Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
Trial: NCT06579846
Drug: Cytisinicline and exercise
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.
Trial: NCT06061692
Drug: Tongxinluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
Trial: NCT06579846
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same intervention as the experimental group without directed exercise prescription
Trial: NCT03769688
Drug: Cervicovaginal secretions
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as arm descriptions
Trial: NCT04863742
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained released dexamethasone, 0.4mg
Trial: NCT04863742
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
Trial: NCT03567694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05589454
Drug: Atorvastatin Calcium tablets 80mg
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Trial: NCT05589454
Drug: Atorvastatin Calcium tablets 20mg
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Trial: NCT05559099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules to match tecovirimat
Trial: NCT06211712
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Trial: NCT05918445
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05555212
Drug: QLH11811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D.
Trial: NCT05990686
Drug: Fentanyl injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~.
Trial: NCT05363592
Drug: CT-L01 12.5/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet, 2 tablets at a time, oral administration
Trial: NCT05411497
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06650384
Drug: Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
Trial: NCT05223673
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
Trial: NCT05223673
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
Trial: NCT05790356
Drug: Fecal Microbial transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
Trial: NCT06717360
Drug: AG2304T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG2304T, QD, PO
Trial: NCT06717360
Drug: AG2304R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG2304R, QD, PO
Trial: NCT04470024
Drug: INCMGA00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
Trial: NCT04743011
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
Trial: NCT04743011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
Trial: NCT05291650
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
Trial: NCT05790447
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
Trial: NCT05863455
Drug: mild sedation and analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
Trial: NCT06091904
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
Trial: NCT06091904
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
Trial: NCT05644873
Drug: control group saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Trial: NCT00000628
Drug: L-697,661
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04767711
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid 25 mg daily for 7 days.
Trial: NCT04608786
Drug: ZKAB001 5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
Trial: NCT04608786
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
Trial: NCT04930354
Drug: ECP-1014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
Trial: NCT05663060
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Formula
Trial: NCT05595109
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice.
Trial: NCT05595109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
Trial: NCT04637529
Drug: S (+) - Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S (+) - Ibuprofen + placebo of Ibuvix®
Trial: NCT04637529
Drug: Ibuvix® - ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuvix® + placebo of S(+) - Ibuprofen
Trial: NCT05437419
Drug: TCK-276
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
Trial: NCT05437419
Drug: TCK-276 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
Trial: NCT05391776
Drug: TST002 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
Trial: NCT05391776
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
Trial: NCT05248841
Drug: US-Lantus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
Trial: NCT05456256
Drug: LP-300
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Trial: NCT04696146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline placebo
Trial: NCT04996667
Drug: inhaled nitric oxide (iNO)
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.